As of 2023, Christopher A. Viehbacher holds a significant investment in Biogen Inc. Common Stock (BIIB). His focus has fluctuated, especially following his appointment as CEO in late 2022, when he committed to buying at least $2 million in company...

As of 2023, Christopher A. Viehbacher holds a significant investment in Biogen Inc. Common Stock (BIIB). His focus has fluctuated, especially following his appointment as CEO in late 2022, when he committed to buying at least $2 million in company stock. Despite not being granted any equity in 2023, his involvement with the stock has remained key to his leadership strategy. The total value of his holdings reflects the company’s performance goals, which he actively shapes, as indicated by his aim to realign the company and cut $1 billion in costs by 2025, emphasizing long-term stockholder value.